Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BlueJays9293on Jan 30, 2024 10:42pm
161 Views
Post# 35854106

RE:RE:RE:Enrolment …

RE:RE:RE:Enrolment …We don't get them often, but I love love love when we get some real colour from the doctors actually fighting in the trenches. When U of Michigan finally got to be one of our trial sites, and they enrolled their very first patient, the head of their ICU said this;

Kyle Gunnerson, MD, FCCM, Professor and Emergency Medicine Director at the Emergency Critical Care Center within the University of Michigan, further noted, “My team and I were very encouraged with the effectiveness of PMX in our first randomized patient within the Tigris trial. We saw rapid improvement and recovery in the patient following administration of PMX and, importantly, the patient was transferred out of the ICU sooner than we anticipated with full discharge from the hospital in under two weeks from admission. With no FDA approved sepsis solution on the market, PMX has the potential to become an effective solution for sepsis and vital for clinical care use around the world. Following the successful treatment of our first randomized patient, my clinical team and I look forward to enrolling more patients into this important study.”

And our beloved Dr. Kellum said this;

Dr. John Kellum, Chief Medical Officer of Spectral, stated, “I am pleased to report our trial site at the University of Michigan has randomized their first patient. The clinical staff at U of M witnessed immediate improvement in the patient’s status following administration of PMX and the patient was able to transfer out of the intensive care unit (ICU) sooner than expected. We believe this positive patient outcome, and the fact that data thus far is exceeding expectations, reinforces our prior EUPHRATES trial data and our overall confidence in the efficacy of PMX in this patient population.”

We are talking about a patient that was on deaths doorstep people.  Hours away from gone, grim reaper just standing there looking at his watch.  And then woosh, blood pressure starts to stabalize, colour in their skin returns, like that's some NO you ain't going to take this one type stuff.  Anyways, keep debating away because conversation is a good thing.



<< Previous
Bullboard Posts
Next >>